Open AccessStratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker
Author(s) -
Ana Batlle-López,
Sonia González De Villambrosía,
Francisco Mazorra,
Sefora Malatxeberria,
Anabel Sáez,
Carlos Montalbán,
Lydia Sánchez,
Juan F. Garcı́a,
Eva GonzálezBarca,
Andrés López,
Ruiz-Marcellan,
Manuela Mollejo,
Carlos Grande,
Harriette Richards,
Hsi,
Alexandar Tzankov,
Carlo Visco,
Zijun Y. Xu-Monette,
Xin Cao,
Ken H. Young,
Miguel Á. Piris,
Eulogio Conde,
Santiago MontesMoreno
Publication year - 2016
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/hrzz-wj80
Subject(s) - chemoimmunotherapy , immunohistochemistry , diffuse large b cell lymphoma , medicine , pathology , lymphoma , rituximab